Analysis of Patient-Reported Symptom Response with Osimertinib (AZD9291) Treatment for Advanced Non-Small-Cell Lung Cancer

被引：0
|
作者：
Novello, Silvia [1 ]
Rudell, Katja [2 ]
Bodnar, Carolyn [2 ]
Vowler, Sarah [2 ]
Rupnik, Tina [3 ]
Ghiorghiu, Serban [2 ]
机构：
[1] Univ Turin, Dept Oncol, Turin, Italy
[2] Astrazeneca, Cambridge, England
[3] Phastar, London, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
osimertinib; symptoms; Non-small-cell lung cancer; Patient-reported outcomes;
D O I：
10.1016/j.jtho.2016.11.1747
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02b-080
引用
收藏
页码：S1238 / S1239
页数：2
相关论文
共 50 条
  • [1] Patient-reported symptom response and impact of treatment with AZD9291 for advanced non-small-cell lung cancer
    Ryden, A.
    Lawrance, R.
    Papadakis, K.
    Ghiorghiu, S.
    Walding, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S606 - S606
  • [2] Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer
    Oxnard, Geoffrey R.
    Thress, Kenneth S.
    Alden, Ryan S.
    Lawrance, Rachael
    Paweletz, Cloud P.
    Cantarini, Mireille
    Yang, James Chih-Hsin
    Barrett, J. Carl
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (28) : 3375 - +
  • [3] AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients
    Remon, Jordi
    Planchard, David
    FUTURE ONCOLOGY, 2015, 11 (22) : 3069 - 3081
  • [4] AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
    Jaenne, Pasi A.
    Yang, James Chih-Hsin
    Kim, Dong-Wan
    Planchard, David
    Ohe, Yuichiro
    Ramalingam, Suresh S.
    Ahn, Myung-Ju
    Kim, Sang-We
    Su, Wu-Chou
    Horn, Leora
    Haggstrom, Daniel
    Felip, Enriqueta
    Kim, Joo-Hang
    Frewer, Paul
    Cantarini, Mireille
    Brown, Kathryn H.
    Dickinson, Paul A.
    Ghiorghiu, Serban
    Ranson, Malcolm
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18): : 1689 - 1699
  • [5] Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo
    Wang, Xin-shuai
    Zhang, Li
    Li, Xiaocen
    Kong, De-jiu
    Hu, Xiao-chen
    Ding, Xue-zhen
    Yang, Jun-qiang
    Zhao, Meng-qi
    He, Yixuan
    Lam, Kit S.
    Gao, She-gan
    Lin, Tzu-yin
    Li, Yuanpei
    NANOMEDICINE, 2018, 13 (10) : 1107 - 1120
  • [6] Patient experience of symptoms and side effects when treated with AZD9291 for advanced non-small-cell lung cancer: A qualitative interview sub-study
    Ryden, A.
    Braam, L.
    Martin, M.
    Walding, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S221 - S221
  • [7] Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line
    Tang, Zheng-Hai
    Jiang, Xiao-Ming
    Guo, Xia
    Fong, Chi Man Vivienne
    Chen, Xiuping
    Lu, Jin-Jian
    ONCOTARGET, 2016, 7 (49) : 81598 - 81610
  • [8] Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial
    Lee, Chee Khoon
    Novello, Silvia
    Ryden, Anna
    Mann, Helen
    Mok, Tony
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18) : 1853 - +
  • [9] Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
    Saad, Nibal
    Poudel, Aarati
    Basnet, Alina
    Gajra, Ajeet
    ONCOTARGETS AND THERAPY, 2017, 10 : 1757 - 1765
  • [10] Patient-reported symptoms and impact of treatment with osimertinib vs chemotherapy for advanced non-small cell lung cancer
    Lee, C. K.
    Novello, S.
    Ryden, A.
    Templeton, A.
    Rudell, K.
    Mann, H.
    Ghiorghiu, S.
    Mok, T.
    ANNALS OF ONCOLOGY, 2017, 28
12345